Zenas Biopharma outlines autoimmune disease pipeline in corporate presentation

Reuters2026/09/02 16:58

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Zenas BioPharma outlined a regulatory path for obexelimab in IgG4-RD, with an FDA decision expected by May 2027.
The Phase 3 INDIGO trial met its primary endpoint, cutting flare risk 56% versus placebo; 73% of patients were flare-free at week 52.
Key secondary endpoints favored obexelimab, including a 37.1% complete remission rate at week 52 versus 19.6% on placebo.
Pipeline update highlighted orelabrutinib Phase 3 programs in PPMS and naSPMS, with trials initiated in 3Q 2025 and 1Q 2026.
Company projected cash runway into 2029, positioning it to commercialize and advance multiple immunology and inflammation programs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zenas Biopharma Inc. published the original content used to generate this news brief on September 02, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Zenas Biopharma outlines autoimmune disease pipeline in corporate presentation

You may also like

Crypto prices